Typhoid Vi Polysaccharide Vaccine

Phase 1Vaccine

Typhoid Vi Polysaccharide Vaccine is one of 5 biologic programs targeting Japanese encephalitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Japanese EncephalitisActive, not recruiting

Post-Traumatic Stress Disorder, PTSDRecruiting

Japanese EncephalitisPreclinical

Active, not recruiting

Post-Traumatic Stress Disorder, PTSDPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Post-Traumatic Stress Disorder, PTSD

#DrugCompanyPhaseTrials

Ritalin

Novartis

Approved

1 2

Inderal

WWyeth-Lederle Vaccines

Phase 3

1 3

Mifeprex

DDanco

Phase 2

2 4

Psilocybin

COMPASS Pathways

Phase 2

2 5

Typhoid Vi Polysaccharide Vaccine

Novartis

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Post-Traumatic Stress Disorder, PTSD

NCT06630884

Clinical

Trials by Indication[1]

Inflammation2 trials

Inflammation and Threat Sensitivity in PTSD

Completed·UUniversity of California, San Francisco·Phase 1·NCT03048929·30 enrolled

Cognitive, Emotional, and Neural Responses to Acute Inflammation

Completed·UUniversity of California, San Francisco·Phase 1·NCT03294564·24 enrolled

Immunogenicity1 trial

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Completed· Novartis logo

Novartis·Phase 3·NCT01466387·552 enrolled

Japanese encephalitis1 trial

Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity

Unknown status·UUniversity of Oxford·N/A·NCT06027801·150 enrolled

Post-Traumatic Stress Disorder, PTSD1 trial

Inflammatory Challenge and Fear Extinction: A Model to Enhance Understanding of Posttraumatic Stress Disorder

Recruiting·UUniversity of California, San Francisco·Phase 1·NCT06630884·288 enrolled

Monkeypox1 trial

SMART (Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster Randomized Controlled Trial)

Active, not recruiting·MMcMaster University·Approved·NCT05745987·3,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Typhoid Vi Polysaccharide Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Typhoid Vi Polysaccharide Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Typhoid Vi Polysaccharide Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: Novartis

Typhoid Vi Polysaccharide Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Inflammation2 trials

Immunogenicity1 trial

Japanese encephalitis1 trial

Post-Traumatic Stress Disorder, PTSD1 trial

Monkeypox1 trial

References

Drug Info

Quick Facts

Related News